Evidence map›Paper›PMID 36369606›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2023

TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4

Tianzhen He, Yibo Chen, De Yang, Md Sahidul Islam, Chon-Kit Chou, Jiarui Liu, Denise L Faustman, Joost J Oppenheim, Xin Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Tianzhen He *State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, SAR, 999078, China.
Yibo Chen *State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, SAR, 999078, China.
De YangCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA.
Md Sahidul IslamState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, SAR, 999078, China.
Chon-Kit ChouState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, SAR, 999078, China.
Jiarui LiuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, SAR, 999078, China.
Denise L FaustmanImmunobiology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Joost J OppenheimCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA. oppenhej@mail.nih.gov.
Xin ChenState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, SAR, 999078, China.
University of Macau · MOCenter for Cancer Research · USHarvard University · USNational Cancer Institute · US

Funding

Guangdong-Hong Kong-Macao Innovation Center sponsored by Guangzhou Development District EF032/ICMS-CX/2021/ RITHGuangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research EF006/ICMS-CX/2021/GDSTCMacau Science and Technology Development Fund 0099/2021/A2 and 0056/2019/AFJUniversidade de Macau CPG2022-00024-ICMS and MYRG2019-00169-ICMS
6 · The paper itself

Abstract

backgroundTNFR2 expression is a characteristic of highly potent immunosuppressive tumor infiltrating CD4

methodTY101, an anti-murine TNFR2 antibody, was used to examine the effect of TNFR2 blockade on Treg proliferation and viability in vitro. The role of TNFR2 on Treg viability was further validated by TNFR2 knockout mice and in the TY101 antagonistic antibody-treated mouse tumor model.

resultsIn this study, we found that an anti-mouse TNFR2 antibody TY101 could inhibit TNF-induced proliferative expansion of Tregs, indicative of an antagonistic property. To examine the effect of TY101 antagonistic antibody on Treg viability, we treated unfractionated lymph node (L.N.) cells with Dexamethasone (Dex) which was known to induce T cell death. The result showed that TY101 antagonistic antibody treatment further promoted Treg death in the presence of Dex. This led us to find that TNFR2 expression was crucial for the survival of Tregs. In the mouse EG7 lymphoma model, treatment with TY101 antagonistic antibody potently inhibited tumor growth, resulting in complete regression of the tumor in 60% of mice. The treatment with TY101 antagonistic antibody elicited potent antitumor immune responses in this model, accompanied by enhanced death of Tregs.

conclusionThis study, therefore, provides clear experimental evidence that TNFR2 antagonistic antibody, TY101, can promote the death of Tregs, and this effect may be attributable to the antitumor effect of TNFR2 antagonistic antibody.

Indexed as

NeoplasmsT-Lymphocytes, RegulatoryAnimalsForkhead Transcription FactorsMiceReceptors, Tumor Necrosis Factor, Type IIForkhead Transcription FactorsFoxp3 protein, mouseReceptors, Tumor Necrosis Factor, Type IICD4+Foxp3+ regulatory T cells (Tregs)Cell deathLymphomaTNFR2TNFR2 antagonistic antibody

Identifiers

PMID36369606
PMCPMC12974723
OpenAlexW4308834773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.